Table 4.

Targetable Molecular Alterations in Non–Small Cell Lung Cancer

Alteration	Incidence Proportion Among Non–Small Cell Lung Cancer in the United States (%)	Potential Therapeutic Agents
EGFR mutation	15-20	Osimertinib, erlotinib, gefitinib, afatinib, dacomitinib
ALK rearrangement	4-5	Alectinib, ceritinib, brigatinib, lorlatinib, crizotinib
ROS1 rearrangement	1-2	Entrectinib, lorlatinib, ceritinib, crizotinib
MET mutation/amplification	2-3	Capmatinib, crizotinib
RET rearrangement	1-2	Selpercatinib, pralsetinib, cabozantinib
HER2 mutation	1-3	Trastuzumab, afatinib, ado-trastuzumab emtamsine
BRAF mutation	1-3	Dabrafenib + trametinib
NTRK fusions	0-1	Larotrectinib, entrectinib
KRAS G12C mutations	10-12	Sotorasib